MYLAN N.V. and Biocon LTD said the European Medicines Agency accepted for review Mylan’s Marketing Authorization Application for a proposed biosimilar trastuzumab, which is used to treat certain HER2-positive breast and gastric cancers. This filing includes analytical, functional and pre-clinical data, as well as results from the pharmacokinetics and confirmatory efficacy/safety global clinical trials for...
Lillian L. Siu discovered her passion while perusing employment ads in the Journal of Clinical Oncology.
